- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma2015 | Publication without faculty affiliation
- Atypical response to anti-PD-1 therapy followed by long-term survival in non-small cell lung cancer - case reports2020 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study2019 | First Faculty of Medicine